| NOVO NORDISK A S Form 6-K July 18, 2016 |
|--|
| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| |
| · |
| |
| FORM 6-K |
| |
| REPORT OF FOREIGN PRIVATE ISSUER |
| Pursuant to Rule 13a-16 or 15d-16 |
| of the Securities Exchange Act of 1934 |
| |
| July 11, 2016 |
| |
| |
| NOVO NORDISK A/S |
| (Exact name of Registrant as specified in its charter) |
| |
| |
| Novo Allé |

DK-2880, Bagsvaerd

Denmark

| (Address of principal executive offices) |
|--|
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F |
| Form 20-F [X] Form 40-F [] |
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934 |
| Yes [] No [X] |
| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82 |

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 11 July 2016 - On 29 April 2016, Novo Nordisk initiated a share repurchase programme under the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003 and in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

Investors:

Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 50 / 2016

CA160711_ShareRepurchase_UK: http://hugin.info/2013/R/2027652/753597.pdf

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: July 11, 2016

Lars Rebien Sørensen,

Chief Executive Officer